Fig. 5
From: Patient-derived xenograft models in cancer therapy: technologies and applications
The weaknesses existing in current PDX models. a Tumor stroma tends to be replaced by murine-derived ECM and stromal cells after several passages, which hinders immune cell activation without human cytokine secretion. b Loss of subclones heterogeneity during the establishment and passage of PDX. c PDX mice have a relatively high risk of spontaneous lymphoma which could cover up accurate results due to the distinct drug sensitivities between lymphoma and other tumors
